PARP inhibitors in BRCA mutation-associated ovarian cancer

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 10-12

  Clamp, Andrew ^a   Jayson, Gordon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ALOPECIA; ANEMIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DYSPEPSIA; FATIGUE; GENE MUTATION; HEADACHE; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NOTE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VOMITING; ANTAGONISTS AND INHIBITORS; FEMALE; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84926092101     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71172-6     Document Type: Note

References (8)

1. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
2. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
3. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010, 28:3570-3576.
4. Tan DSP, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530-5536.
5. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012, 366:1382-1392.
6. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014, 15:852-861.
7. Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2014, published online Dec 4. http://dx.doi.org/10.1016/S1470-2045(14)71135-0.
8. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014, 15:1207-1214.